In this story
Big Pharma is reduced – for now – the potential negative impacts of the president of the Chinese tariffs Donald Trump on their industry.
Merck (Mrk-9.01%) The main financial officer Caroline Litchfield said on Tuesday on Tuesday during the salary on the invitation for the company to expect a “highly intangible effect” from the tariff.
Trump in the beginning Have been announced last Saturday for 25% tariffs On imports from Mexico and Canada, with a lower 10% tariff on Canadian energy exports. In addition, imports from China faces 10% tariff. All tariffs should have entered into force on Tuesday and remain in place until these countries take the flow of undocumented immigrants and illegal drugs in the USA, according to the USA White house.
On Monday morning, Trump announced a one-month break Mexico and Canada Tariffs – but these are the remaining Chinese tariffs that are concerned of the pharmaceutical industries.
Litchfield said that the company has a production imprint that “really allows the global supply” with low production levels in China, Mexico and Canada.
“We will continue to assess the situation based on different tariffs proposed by the US government, but they remain safe in our supply chain and our ability to supply our medicines and vaccines around the world,” Litchfield told investors.
Tariffs did not appear at all during Pfizer (Pfe-1.05%) or amgen (Amgn+ 0.04%) An earnest call on Tuesday. The Chief Director of Pfizer Albert Bourl, however, answered some questions on another hot political topic – Robert F. Kennedy JR Nomination as Trump Health Secretary.
In contrast, some trade groups have warned against tariffs.
The Association Distribution and Association for Accessible Medicines exhibited a statement, warning that the tariffs could disrupt the industry supply chain and affect American patients, especially those who rely on generic drugs.
“From the basic ingredients to finished products, US medications rely on a global supply chain that is already emphasized and needing to strengthen” John Murphy III, the president and the executive of associations for affordable medicines, said UA statement. “Tariffs on products from Canada, Mexico and China could increase already problematic drug shortcomings.”
2025-02-04 23:00:00
